{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:16:32Z","timestamp":1784175392035,"version":"3.55.0"},"reference-count":82,"publisher":"Medknow","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Mycobacteriol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/ijmy.ijmy_85_17","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T09:26:59Z","timestamp":1501666019000},"page":"213","source":"Crossref","is-referenced-by-count":37,"title":["Fighting tuberculosis by drugs targeting nonreplicating <i>Mycobacterium tuberculosis<\/i> bacilli"],"prefix":"10.4103","volume":"6","author":[{"given":"Lanfranco","family":"Fattorini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Iacobino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Piccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Giannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mustazzolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2581","reference":[{"key":"key-10.4103\/2212-5531.211934-1","unstructured":"World Health Organization. Global Tuberculosis Report. WHO\/HTM\/TB\/2016.13. Geneva, Switzerland: World Health Organization; 2016."},{"key":"key-10.4103\/2212-5531.211934-2","unstructured":"World Health Organization. A Global Action Framework for TB Research in Support of the Third Pillar of WHO's End TB Strategy. WHO\/HTM\/TB\/2015.26. Geneva, Switzerland: World Health Organization; 2015."},{"key":"key-10.4103\/2212-5531.211934-3","first-page":"220","volume-title":"Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies","author":"Zumla","year":"2015","journal-title":"Lancet Respir Med"},{"key":"key-10.4103\/2212-5531.211934-4","first-page":"16076","volume-title":"Tuberculosis","author":"Pai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"key-10.4103\/2212-5531.211934-5","first-page":"343","volume-title":"Latent tuberculosis infection: Myths, models, and molecular mechanisms","author":"Dutta","year":"2014","journal-title":"Microbiol Mol Biol Rev"},{"key":"key-10.4103\/2212-5531.211934-6","first-page":"2127","volume-title":"Latent Mycobacterium tuberculosis infection","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2212-5531.211934-7","first-page":"970","volume-title":"Primary care screening and treatment for latent tuberculosis infection in adults: Evidence Report and Systematic Review for the US Preventive Services Task Force","author":"Kahwati","year":"2016","journal-title":"JAMA"},{"key":"key-10.4103\/2212-5531.211934-8","first-page":"845","volume-title":"The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies","author":"Barry","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"key-10.4103\/2212-5531.211934-9","first-page":"288","volume-title":"Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses","author":"Lenaerts","year":"2015","journal-title":"Immunol Rev"},{"key":"key-10.4103\/2212-5531.211934-10","first-page":"159","volume-title":"The path of anti-tuberculosis drugs: From blood to lesions to mycobacterial cells","author":"Dartois","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"key-10.4103\/2212-5531.211934-11","first-page":"833","volume-title":"Mycobacterium tuberculosis in the extracellular compartment: An underestimated adversary","author":"Grosset","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-12","first-page":"258","volume-title":"Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism","author":"Kim","year":"2010","journal-title":"EMBO Mol Med"},{"key":"key-10.4103\/2212-5531.211934-13","first-page":"e2013072","volume-title":"Targeting dormant bacilli to fight tuberculosis","author":"Fattorini","year":"2013","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"key-10.4103\/2212-5531.211934-14","first-page":"e00342","volume-title":"The importance of first impressions: Early events in Mycobacterium tuberculosis infection influence outcome","author":"Cadena","year":"2016","journal-title":"MBio"},{"key":"key-10.4103\/2212-5531.211934-15","first-page":"e75","volume-title":"Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum","author":"Garton","year":"2008","journal-title":"PLoS Med"},{"key":"key-10.4103\/2212-5531.211934-16","first-page":"1648","volume-title":"Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis","author":"Sarathy","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-17","first-page":"133","volume-title":"New strategies for antibacterial drug design: Targeting non-multiplying latent bacteria","author":"Coates","year":"2006","journal-title":"Drugs R D"},{"key":"key-10.4103\/2212-5531.211934-18","first-page":"1223","volume-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","author":"Prideaux","year":"2015","journal-title":"Nat Med"},{"key":"key-10.4103\/2212-5531.211934-19","first-page":"552","volume-title":"Prediction of Drug Penetration in Tuberculosis Lesions","author":"Sarathy","year":"2016","journal-title":"ACS Infect Dis"},{"key":"key-10.4103\/2212-5531.211934-20","first-page":"2062","volume-title":"An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence","author":"Wayne","year":"1996","journal-title":"Infect Immun"},{"key":"key-10.4103\/2212-5531.211934-21","first-page":"201","volume-title":"In vitro models that utilize hypoxia to induce non-replicating persistence in Mycobacteria","author":"Sohaskey","year":"2015","journal-title":"Methods Mol Biol"},{"key":"key-10.4103\/2212-5531.211934-22","first-page":"833","volume-title":"Rv3133c\/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis","author":"Park","year":"2003","journal-title":"Mol Microbiol"},{"key":"key-10.4103\/2212-5531.211934-23","first-page":"717","volume-title":"Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling","author":"Betts","year":"2002","journal-title":"Mol Microbiol"},{"key":"key-10.4103\/2212-5531.211934-24","first-page":"705","volume-title":"Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program","author":"Voskuil","year":"2003","journal-title":"J Exp Med"},{"key":"key-10.4103\/2212-5531.211934-25","first-page":"5789","volume-title":"Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance","author":"de","year":"2009","journal-title":"J Med Chem"},{"key":"key-10.4103\/2212-5531.211934-26","first-page":"6358","volume-title":"Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide","author":"Hu","year":"2000","journal-title":"J Bacteriol"},{"key":"key-10.4103\/2212-5531.211934-27","first-page":"4150","volume-title":"Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis","author":"Sala","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-28","doi-asserted-by":"crossref","unstructured":"Salina EG, Waddell SJ, Hoffmann N, Rosenkrands I, Butcher PD, Kaprelyants AS. Potassium availability triggers Mycobacterium tuberculosis transition to, and resuscitation from, non-culturable (dormant) states. Open Biol 2014;4. pii: 140106.","DOI":"10.1098\/rsob.140106"},{"key":"key-10.4103\/2212-5531.211934-29","first-page":"131","volume-title":"Defining dormancy in mycobacterial disease","author":"Lipworth","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"key-10.4103\/2212-5531.211934-30","first-page":"641","volume-title":"Dormancy models for Mycobacterium tuberculosis: A minireview","author":"Alnimr","year":"2015","journal-title":"Braz J Microbiol"},{"key":"key-10.4103\/2212-5531.211934-31","first-page":"S10","volume-title":"Systematic analysis of hollow fiber model of tuberculosis experiments","author":"Pasipanodya","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key-10.4103\/2212-5531.211934-32","first-page":"453","volume-title":"Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis","author":"Franzblau","year":"2012","journal-title":"Tuberculosis (Edinb)"},{"key":"key-10.4103\/2212-5531.211934-33","first-page":"e1502","volume-title":"The enduring hypoxic response of Mycobacterium tuberculosis","author":"Rustad","year":"2008","journal-title":"PLoS One"},{"key":"key-10.4103\/2212-5531.211934-34","first-page":"565","volume-title":"Mycobacterium tuberculosis gene expression at different stages of hypoxia-induced dormancy and upon resuscitation","author":"Iona","year":"2016","journal-title":"J Microbiol"},{"key":"key-10.4103\/2212-5531.211934-35","first-page":"219","volume-title":"Formation, physiology, ecology, evolution and clinical importance of bacterial persisters","author":"Van","year":"2017","journal-title":"FEMS Microbiol Rev"},{"key":"key-10.4103\/2212-5531.211934-36","doi-asserted-by":"crossref","unstructured":"Gold B, Nathan C. 2017. Targeting phenotypically tolerant Mycobacterium tuberculosis. Microbiol Spectrum 5:TBTB2-0031-2016. doi:10.1128\/microbiolspec.TBTB2-0031-2016.","DOI":"10.1128\/microbiolspec.TBTB2-0031-2016"},{"key":"key-10.4103\/2212-5531.211934-37","first-page":"e00100","volume-title":"Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters","author":"Keren","year":"2011","journal-title":"MBio"},{"key":"key-10.4103\/2212-5531.211934-38","first-page":"1002","volume-title":"Multiple toxin-antitoxin systems in Mycobacterium tuberculosis","author":"Sala","year":"2014","journal-title":"Toxins (Basel)"},{"key":"key-10.4103\/2212-5531.211934-39","doi-asserted-by":"crossref","unstructured":"Sebastian J, Swaminath S, Nair RR, Jakkala K, Pradhan A, Ajitkumar P. De novo emergence of genetically resistant mutants of Mycobacterium tuberculosis from the persistence phase cells formed against antituberculosis drugs in vitro. Antimicrob Agents Chemother 2017;61. pii: e01343-16.","DOI":"10.1128\/AAC.01343-16"},{"key":"key-10.4103\/2212-5531.211934-40","first-page":"7527","volume-title":"Rifampin induces hydroxyl radical formation in Mycobacterium tuberculosis","author":"Piccaro","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-41","first-page":"1428","volume-title":"Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions","author":"Piccaro","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-42","first-page":"711","volume-title":"Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis","author":"Piccaro","year":"2015","journal-title":"J Antibiot (Tokyo)"},{"key":"key-10.4103\/2212-5531.211934-43","doi-asserted-by":"crossref","unstructured":"Iacobino A, Piccaro G, Giannoni F, Mustazzolu A, Fattorini L. Mycobacterium tuberculosis is selectively killed by rifampin and rifapentine in hypoxia at neutral pH. Antimicrob Agents Chemother 2017;61. pii: E02296-16.","DOI":"10.1128\/AAC.02296-16"},{"key":"key-10.4103\/2212-5531.211934-44","first-page":"1537","volume-title":"Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis","author":"Iona","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-45","first-page":"25273","volume-title":"Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis","author":"Koul","year":"2008","journal-title":"J Biol Chem"},{"key":"key-10.4103\/2212-5531.211934-46","first-page":"2712","volume-title":"Activity of drug combinations against dormant Mycobacterium tuberculosis","author":"Filippini","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-47","first-page":"218","volume-title":"Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor","author":"Somasundaram","year":"2013","journal-title":"BMC Microbiol"},{"key":"key-10.4103\/2212-5531.211934-48","first-page":"6521","volume-title":"Rapid, semiquantitative assay to discriminate among compounds with activity against replicating or nonreplicating Mycobacterium tuberculosis","author":"Gold","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-49","first-page":"4778","volume-title":"Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates","author":"Xie","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-50","first-page":"627","volume-title":"Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis","author":"Paramasivan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-51","first-page":"653","volume-title":"Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis","author":"Hu","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-52","first-page":"317","volume-title":"Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis","author":"Hu","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.4103\/2212-5531.211934-53","first-page":"69","volume-title":"Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis","author":"Hu","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.4103\/2212-5531.211934-54","first-page":"641","volume-title":"High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo","author":"Hu","year":"2015","journal-title":"Front Microbiol"},{"key":"key-10.4103\/2212-5531.211934-55","first-page":"5782","volume-title":"Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis","author":"Zhang","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-56","first-page":"3217","volume-title":"In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis","author":"Zhang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-57","first-page":"4012","volume-title":"Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis","author":"Vocat","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-58","first-page":"4457","volume-title":"Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis","author":"Lechartier","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-59","first-page":"857","volume-title":"Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents","author":"Lakshminarayana","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/2212-5531.211934-60","first-page":"81","volume-title":"Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability","author":"Gengenbacher","year":"2010","journal-title":"Microbiology"},{"key":"key-10.4103\/2212-5531.211934-61","first-page":"1380","volume-title":"Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis","author":"Cho","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-62","first-page":"136","volume-title":"In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis","author":"Upton","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-63","first-page":"2054","volume-title":"Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis","author":"Wayne","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-64","first-page":"127","volume-title":"Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis","author":"Sulochana","year":"2009","journal-title":"J Chemother"},{"key":"key-10.4103\/2212-5531.211934-65","first-page":"5485","volume-title":"Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis","author":"Tasneen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-66","first-page":"2045","volume-title":"Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice","author":"Dutta","year":"2014","journal-title":"Am J Pathol"},{"key":"key-10.4103\/2212-5531.211934-67","first-page":"4331","volume-title":"Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis","author":"Rosenthal","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-68","first-page":"4026","volume-title":"Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-69","first-page":"3114","volume-title":"Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis","author":"Williams","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-70","first-page":"129","volume-title":"Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis","author":"Tasneen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-71","first-page":"270","volume-title":"Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis","author":"Tasneen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-72","first-page":"603","volume-title":"Heterogeneous disease progression and treatment response in a C3HeB\/FeJ mouse model of tuberculosis","author":"Lanoix","year":"2015","journal-title":"Dis Model Mech"},{"key":"key-10.4103\/2212-5531.211934-73","first-page":"735","volume-title":"Selective inactivity of pyrazinamide against tuberculosis in C3HeB\/FeJ mice is best explained by neutral pH of caseum","author":"Lanoix","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-74","first-page":"2316","volume-title":"Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis","author":"Lanoix","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-75","first-page":"1091","volume-title":"Sterilizing activity of pyrazinamide in combination with first-line drugs in a C3HeB\/FeJ mouse model of tuberculosis","author":"Lanoix","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-76","first-page":"e17550","volume-title":"Location of intra- and extracellular M.tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment","author":"Hoff","year":"2011","journal-title":"PLoS One"},{"key":"key-10.4103\/2212-5531.211934-77","first-page":"251","volume-title":"Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in Mycobacterium tuberculosis infected C3HeB\/FeJ mice","author":"Irwin","year":"2016","journal-title":"ACS Infect Dis"},{"key":"key-10.4103\/2212-5531.211934-78","first-page":"4026","volume-title":"Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas","author":"Irwin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/2212-5531.211934-79","first-page":"1","volume-title":"Latent tuberculosis (TB) bacilli: Yes or no to preventive chemotherapy","author":"Velayati","year":"2012","journal-title":"Int J Mycobacteriol","ISSN":"https:\/\/id.crossref.org\/issn\/2212-5531","issn-type":"print"},{"key":"key-10.4103\/2212-5531.211934-80","first-page":"66","volume-title":"Populations of latent Mycobacterium tuberculosis lack a cell wall: Isolation, visualization, and whole-genome characterization","author":"Velayati","year":"2016","journal-title":"Int J Mycobacteriol","ISSN":"https:\/\/id.crossref.org\/issn\/2212-5531","issn-type":"print"},{"key":"key-10.4103\/2212-5531.211934-81","first-page":"39","volume-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: A multi-arm, multi-stage randomised controlled trial","author":"Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key-10.4103\/2212-5531.211934-82","first-page":"TNMI7","volume-title":"Treatment of latent tuberculosis infection?","author":"Haley","year":"2017","journal-title":"Microbiol Spectrum"}],"container-title":["International Journal of Mycobacteriology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T12:52:40Z","timestamp":1682081560000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ijmyco.org\/text.asp?2017\/6\/3\/213\/211934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"alternative-id":["211934"],"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_85_17","relation":{},"ISSN":["2212-5531"],"issn-type":[{"value":"2212-5531","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}